COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN

被引：1
|
作者：
Shibahara, H. [1 ]
Shiroiwa, T. [2 ]
Nakamura, K. [1 ]
Shimozuma, K. [1 ]
机构：
[1] Ritsumeikan Univ, Kusatsu, Japan
[2] Natl Inst Publ Hlth, Saitama, Japan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.532
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A415 / A416
页数：2
相关论文
共 50 条
  • [41] Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel
    Bilgetekin, Irem
    Basal, Fatma Bugdayci
    Cinkir, Havva Yesil
    Esin, Ece
    Oksuzoglu, Berna
    Demirci, Umut
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2020, 30 (08): : 815 - 821
  • [42] Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer
    Ramamurthy, Chethan
    Handorf, Elizabeth A.
    Correa, Andres F.
    Beck, J. Robert
    Geynisman, Daniel M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (10) : 688 - 695
  • [43] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
    Cheng, H. H.
    Gulati, R.
    Azad, A.
    Nadal, R.
    Twardowski, P.
    Vaishampayan, U. N.
    Agarwal, N.
    Heath, E. I.
    Pal, S. K.
    Rehman, H-t
    Leiter, A.
    Batten, J. A.
    Montgomery, R. B.
    Galsky, M. D.
    Antonarakis, E. S.
    Chi, K. N.
    Yu, E. Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) : 122 - 127
  • [44] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
    Schweizer, Michael T.
    Zhou, Xian C.
    Wang, Hao
    Bassi, Sunakshi
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    EUROPEAN UROLOGY, 2014, 66 (04) : 646 - 652
  • [45] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
    H H Cheng
    R Gulati
    A Azad
    R Nadal
    P Twardowski
    U N Vaishampayan
    N Agarwal
    E I Heath
    S K Pal
    H-t Rehman
    A Leiter
    J A Batten
    R B Montgomery
    M D Galsky
    E S Antonarakis
    K N Chi
    E Y Yu
    Prostate Cancer and Prostatic Diseases, 2015, 18 : 122 - 127
  • [46] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12) : 1231 - 1240
  • [47] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [48] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [49] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    M. Koninckx
    J. L. Marco
    I. Pérez
    M. T. Faus
    V. Alcolea
    F. Gómez
    Clinical and Translational Oncology, 2019, 21 : 314 - 323
  • [50] Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharide, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 428 - 432
12345